Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$29.1MCash on Hand
10.5mo Cash Runway
Follow ELUT by emailGet an email when ELUT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ELUT, unsubscribe in one click. Privacy
📣 What ELUT Says Is Next
fourth quarter of 2026 · “Elutia also intends to submit NXT-41x, its leading drug delivery program, to FDA in the fourth quarter of 2026, following positive results from a key performance study supporting the submission.”
Company press release, Nov 5, 2026 · SEC filing
first half of 2027 · “After adding $26 million without an equity offering, we believe we have the technology, the team, and the capital to advance NXT-41x toward anticipated clearance in the first half of 2027 and through the first full year of commercial launch in 2028.”
Company press release, Nov 5, 2026 · SEC filing
in 2028 · “And we believe we have the team and capital to execute.” Capital Secured to Support NXT-41x Through Clearance and Commercial Launch Elutia has secured up to $26 million of additional capital to support the Company through the anticipated clearance of NXT-41x and its first full year of commercial launch in 2028, without an equity offering:”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Earnings Elutia reported Q3 2026 net sales of $1.1 million, up 20.4%, and a net loss of $1.3 million, including $5.2 million income from discontinued operations. It raised $26 million without an equity offering and plans an NXT-41x FDA submission in Q4 2026. Form 8-K · SEC filing · Press release
Aug 21, 2026 ·
Deal Elutia completed the sale of its SimpliDerm business to Cellution Biologics on August 17, 2026, receiving $7.7 million at closing, with up to $3 million more in contingent payments over 18 months. The company also amended its loan agreement to release the lien on the assets. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 13, 2026 ·
Earnings Q2 2026 net sales were $2.4 million, down from $2.7 million, with GAAP gross margin of 59.6% and a $7.6 million net loss. The company secured up to $26 million to fund NXT-41x through launch, and NXT-41 FDA clearance is expected in 4Q 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · N/A · Active Trial · EluPro Antibiotic-Eluting BioEnvelope Registry Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
ELUT holds $29.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.3M/quarter from operations,
an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELUT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.